IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small cell lung cancer. The unique adverse events that can arise after treatment with ICIs are known as immune-related adverse events (irAE). As the number of cases under treatment with ICIs increases, new typ...
Main Authors: | Takeshi Terashima, Eri Iwami, Takashi Shimada, Aoi Kuroda, Tatsu Matsuzaki, Takahiro Nakajima, Aya Sasaki, Keisuke Eguchi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12890-020-1150-x |
Similar Items
-
Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
by: Emma Sanderson, et al.
Published: (2020-04-01) -
Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
by: Kensuke Kanaoka, et al.
Published: (2020-06-01) -
Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report
by: Maël Domblides, et al.
Published: (2021-04-01) -
Skin puckering and edema during durvalumab therapy
by: Brianna Olamiju, BA, et al.
Published: (2021-01-01) -
Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
by: Ryosuke Imai, et al.
Published: (2021-04-01)